ESMO-IO 2017 - ESMO Immuno Oncology Congress
Dec 07 - Dec 10, 2017 | GenevaSwitzerland
LARVOL is not affiliated with ESMO Immuno Oncology Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 20 abstracts linked to Trials
Primary PFS and safety analyses of a randomized Phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)
PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC
IMA950 multipeptide vaccine adjuvanted with poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients
Phase 1 study of E7046, a PGE2 receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment (TME)
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
Efficacy of PEGylated human IL-10 (AM0010) in combination with anti-PD-1 blockade in patients (pts) with metastatic renal cell carcinoma (mRCC): A phase 1b trial
INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12) immunotherapy in biochemically relapsed prostate cancer
Deciphering the intra-tumoural T cell receptor repertoire in patients with NSCLC within the lung TRACERx study
A Phase 1b/2 Study of Omaveloxolone in Combination with Checkpoint Inhibitors in Patients with Unresectable or Metastatic Melanoma
T cell responses in patients with melanoma resistant to multiple immunotherapies
T-cell therapy in combination with vemurafenib in BRAF mutated metastatic melanoma patients
Health Status of Patients (Pts) with Gastric Cancer (GC) Receiving Nivolumab Monotherapy In CheckMate-032 (CM-032) and Predicted Scores for ATTRACTION-2
A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy
KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)
Peptide vaccination against PD-L1 in multiple myeloma: A phase I trial